KEMRI-Wellcome Trust Research Programme, Nairobi, Kenya.
Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK.
Malar J. 2018 May 29;17(1):213. doi: 10.1186/s12936-018-2364-8.
Change of severe malaria treatment policy from quinine to artesunate, a major malaria control advance in Africa, is compromised by scarce data to monitor policy translation into practice. In Kenya, hospital surveys were implemented to monitor health systems readiness and inpatient malaria case-management.
All 47 county referral hospitals were surveyed in February and October 2016. Data collection included hospital assessments, interviews with inpatient health workers and retrospective review of patients' admission files. Analysis included 185 and 182 health workers, and 1162 and 1224 patients admitted with suspected malaria, respectively, in all 47 hospitals. Cluster-adjusted comparisons of the performance indicators with exploratory stratifications were performed.
Malaria microscopy was universal during both surveys. Artesunate availability increased (63.8-85.1%), while retrospective stock-outs declined (46.8-19.2%). No significant changes were observed in the coverage of artesunate trained (42.2% vs 40.7%) and supervised health workers (8.7% vs 12.8%). The knowledge about treatment policy improved (73.5-85.7%; p = 0.002) while correct artesunate dosing knowledge increased for patients < 20 kg (42.7-64.6%; p < 0.001) and > 20 kg (70.3-80.8%; p = 0.052). Most patients were tested on admission (88.6% vs 92.1%; p = 0.080) while repeated malaria testing was low (5.2% vs 8.1%; p = 0.034). Artesunate treatment for confirmed severe malaria patients significantly increased (69.9-78.7%; p = 0.030). No changes were observed in artemether-lumefantrine treatment for non-severe test positive patients (8.0% vs 8.8%; p = 0.796). Among test negative patients, increased adherence to test results was observed for non-severe (68.6-78.0%; p = 0.063) but not for severe patients (59.1-62.1%; p = 0.673). Overall quality of malaria case-management improved (48.6-56.3%; p = 0.004), both for children (54.1-61.5%; p = 0.019) and adults (43.0-51.0%; p = 0.041), and in both high (51.1-58.1%; p = 0.024) and low malaria risk areas (47.5-56.0%; p = 0.029).
Most health systems and malaria case-management indicators improved during 2016. Gaps, often specific to different inpatient populations and risk areas, however remain and further programmatic interventions including close monitoring is needed to optimize policy translation.
奎宁向青蒿琥酯的重度疟疾治疗政策转变是非洲主要的疟疾控制进展,但缺乏监测政策转化为实践的数据。在肯尼亚,进行了医院调查以监测卫生系统的准备情况和住院疟疾病例管理。
2016 年 2 月和 10 月对所有 47 个县转诊医院进行了调查。数据收集包括医院评估、对住院卫生工作者的访谈以及对患者入院档案的回顾性审查。分析包括在所有 47 家医院中分别对 185 名和 182 名卫生工作者以及 1162 名和 1224 名疑似疟疾住院患者进行了分析。对具有探索性分层的绩效指标进行了聚类调整比较。
两次调查均普遍进行疟疾显微镜检查。青蒿琥酯的供应增加(63.8-85.1%),而回顾性缺货减少(46.8-19.2%)。接受青蒿琥酯培训的卫生工作者(42.2%比 40.7%)和接受监督的卫生工作者(8.7%比 12.8%)的覆盖率无显著变化。治疗政策的知识有所提高(73.5-85.7%;p=0.002),而对体重<20kg(42.7-64.6%;p<0.001)和体重>20kg(70.3-80.8%;p=0.052)的患者正确的青蒿琥酯剂量知识有所提高。大多数患者在入院时接受检测(88.6%比 92.1%;p=0.080),而重复疟疾检测率较低(5.2%比 8.1%;p=0.034)。确诊的严重疟疾患者接受青蒿琥酯治疗的比例显著增加(69.9-78.7%;p=0.030)。对非严重测试阳性患者使用青蒿琥酯-甲氟喹治疗没有变化(8.0%比 8.8%;p=0.796)。在测试阴性的患者中,非严重疾病患者对测试结果的依从性提高(68.6-78.0%;p=0.063),但严重疾病患者没有(59.1-62.1%;p=0.673)。疟疾病例管理的整体质量有所提高(48.6-56.3%;p=0.004),儿童(54.1-61.5%;p=0.019)和成人(43.0-51.0%;p=0.041)以及高(51.1-58.1%;p=0.024)和低疟疾风险地区(47.5-56.0%;p=0.029)均有改善。
2016 年期间,大多数卫生系统和疟疾病例管理指标都有所改善。然而,仍存在差距,这些差距通常是特定于不同的住院人群和风险地区的,需要进一步的方案干预措施,包括密切监测,以优化政策的转化。